Welcome to our dedicated page for Erasca SEC filings (Ticker: ERAS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Erasca, Inc. filings document a clinical-stage oncology issuer focused on RAS/MAPK pathway-driven cancers and common stock listed on the Nasdaq Global Select Market. Recent Form 8-K reports disclose ERAS-0015 clinical data from AURORAS-1 and JYP0015M101, Regulation FD materials, financial results, cash and marketable-securities information, and common-stock offering activity under a shelf registration statement.
Proxy materials cover annual meeting procedures, director elections, executive compensation, and stockholder voting matters. Other event reports record intellectual-property correspondence involving ERAS-0015 and provide formal updates on the company's pipeline, capital structure, and public-company governance.
Erasca, Inc. held its annual meeting of stockholders on June 26, 2026. As of the April 27, 2026 record date, 310,965,971 shares were entitled to vote, and 266,073,906 shares were represented in person or by proxy, establishing a strong quorum.
Stockholders elected three Class II directors—Alexander W. Casdin, Julie Hambleton, M.D., and Michael D. Varney, Ph.D.—to three-year terms expiring at the 2029 annual meeting. Votes for these nominees ranged from 219,569,944 to 223,863,013, with 25,593,152 to 29,886,221 withheld and 16,617,741 broker non-votes.
Stockholders also ratified the appointment of KPMG LLP as Erasca’s independent registered public accounting firm for the fiscal year ending December 31, 2026, with no broker non-votes recorded for this proposal.
Erasca, Inc. director Valerie Denise Harding received a stock option grant covering 29,888 shares of Common Stock. The options have an exercise price of $16.01 per share and expire on June 26, 2036.
All 29,888 options vest on June 26, 2027, provided she remains in continuous service with the company through that date. Following this grant, she holds 29,888 derivative securities directly, reflecting a routine, compensation-related award rather than an open-market purchase or sale.
Erasca, Inc. director Jean I. Liu received a stock option grant covering 29,888 shares of common stock on June 26, 2026. The option has an exercise price of $16.01 per share and expires on June 26, 2036. According to the filing, Liu now holds options for 29,888 shares following this award. The grant vests 100% on June 26, 2027, subject to her continuous service with the company until that date, and represents equity compensation rather than an open-market purchase or sale.
Erasca, Inc. director Pratik S. Multani received a stock option grant covering 29,888 shares of common stock. The option has an exercise price of $16.01 per share and expires on June 26, 2036.
All of these options vest on June 26, 2027, as long as the director continues to serve the company through that date. After this grant, the filing shows 29,888 option shares held directly, with no remaining prior derivative positions listed.
Erasca, Inc. director Alexander W. Casdin received a grant of stock options covering 29,888 shares of common stock. The options have an exercise price of $16.01 per share, expire on June 26, 2036, and vest 100% on June 26, 2027, contingent on his continued service.
Erasca, Inc. director Julie Hambleton reported receiving a stock option grant as part of her compensation. She was awarded options covering 29,888 shares of common stock at an exercise price of $16.01 per share. These options vest 100% on June 26, 2027, provided she continues serving the company through that date, and expire on June 26, 2036. Following this grant, she holds stock options for 29,888 shares directly. This is a compensation-related award rather than an open-market purchase or sale.
Erasca, Inc. director James Arthur Bristol received a grant of stock options as part of his compensation. The award covers 29,888 options to buy common stock at an exercise price of $16.01 per share. These options were granted at no cost on the grant date.
The options vest 100% on June 26, 2027, provided he continues serving the company through that date, and they expire on June 26, 2036. After this grant, he holds 29,888 stock options directly, with no open-market share purchases or sales reported in this filing.
Erasca, Inc. filed a Form 144 reporting proposed sales and a prior donation of common stock.
The filing lists a donation dated 07/20/2021 and shows the Erasca Foundation sold common shares on 03/16/2026, 04/15/2026, and 05/15/2026 with amounts 116,855.46, 150,843.19, and 84,528.29 respectively. The entry references Merrill Lynch and includes addresses for the foundation and transfer agent.
Erasca Foundation reported sales of common stock in multiple transactions. The excerpt lists three sales of 8,333 shares each on 04/15/2026, 03/16/2026, and 02/17/2026 with cash values shown per transaction. The filings present past three‑month dispositions by the foundation; timing and counterparty details are as listed.
Erasca, Inc. group files an amendment reporting beneficial ownership positions as of March 31, 2026. The Reporting Persons — a Venrock healthcare group and two named individuals — indicate beneficial ownership of 16,382,812 shares, representing 5.3% of Erasca's common stock based on 310,806,888 shares outstanding as of March 31, 2026. The filing breaks the position into 2,676,745 shares held by VHCP III, 267,632 shares held by VHCP Co-Investment III, and 13,438,435 shares held by VHCP EG. The report states shared voting and dispositive power for these holdings and incorporates related cover-page figures by reference.